BELLUS Health Inc.

2.8000.00Vol 112.18K1Y Perf 8.30%
Jul 23rd, 2021 16:00 DELAYED
BID2.79 ASK2.80
Open2.91 Previous Close2.80
Pre-Market- After-Market-
 - -  - -%
Target Price
8.33 
Analyst Rating
Strong Buy 1.22
Potential %
197.50 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     58.47
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     55.67
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap219.34M 
Earnings Rating
Price Range Ratio 52W %
26.78 
Earnings Date
12th Aug 2021

Today's Price Range

2.762.93

52W Range

2.014.96

5 Year PE Ratio Range

-13.00704.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
2.19%
1 Month
-15.15%
3 Months
-34.43%
6 Months
-27.08%
1 Year
8.30%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BLU2.800.00000.00
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
17.20
18.10
0.00
0.00
-666.40
Leverage Ratio 1.00
ProfitabilityValueIndustryS&P 500US Markets
-
-248 800.00
-247 607.00
-67 041.80
-
RevenueValueIndustryS&P 500US Markets
10.40K
0.00
-41.10
-65.80
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.15-0.20-33.33
Q04 2020-0.13-0.1023.08
Q03 2020-0.16-0.0943.75
Q02 2020-0.19-0.1426.32
Q01 2020-0.18-0.180.00
Q04 2019-0.12-0.18-50.00
Q03 2019-0.11-0.14-27.27
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2021
Estimated EPS Next Report-0.20
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume112.18K
Shares Outstanding78.34M
Trades Count979
Dollar Volume9.14M
Avg. Volume920.85K
Avg. Weekly Volume306.75K
Avg. Monthly Volume475.66K
Avg. Quarterly Volume434.77K

BELLUS Health Inc. (NASDAQ: BLU) stock closed at 2.8 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 112.18K shares and market capitalization of 219.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. BELLUS Health Inc. CEO is Roberto Bellini.

The one-year performance of BELLUS Health Inc. stock is 8.3%, while year-to-date (YTD) performance is -8.5%. BLU stock has a five-year performance of %. Its 52-week range is between 2.01 and 4.96, which gives BLU stock a 52-week price range ratio of 26.78%

BELLUS Health Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 2.12, a price-to-sale (PS) ratio of 21 613.90, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.83%, a ROC of -29.23% and a ROE of -27.91%. The company’s profit margin is -%, its EBITDA margin is -247 607.00%, and its revenue ttm is $10.40 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from BELLUS Health Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. BELLUS Health Inc.’s next earnings report date is 12th Aug 2021.

The consensus rating of Wall Street analysts for BELLUS Health Inc. is Strong Buy (1.22), with a target price of $8.33, which is +197.50% compared to the current price. The earnings rating for BELLUS Health Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BELLUS Health Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BELLUS Health Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.26, ATR14 : 0.17, CCI20 : -61.57, Chaikin Money Flow : -0.27, MACD : -0.16, Money Flow Index : 30.33, ROC : -3.45, RSI : 37.05, STOCH (14,3) : 32.26, STOCH RSI : 0.76, UO : 44.93, Williams %R : -67.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BELLUS Health Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.22
Strong Buy
1.22
Strong Buy
1.22

BELLUS Health Inc.

BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, development of drug candidates for health solutions.

CEO: Roberto Bellini

Telephone: +1 450 680-4525

Address: 275 Armand-Frappier Boulevard, Laval H7V 4A7, QC, CA

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

Bearish Bullish

55%45%

News

Stocktwits